Kallmann Syndrome

1. Clinical Overview

Summary

Kallmann Syndrome (KS) is a rare genetic disorder characterised by the unique combination of Congenital Hypogonadotropic Hypogonadism (CHH) and Anosmia or Hyposmia (absent or reduced sense of smell). The syndrome results from failure of GnRH (Gonadotropin-Releasing Hormone) neurons to migrate from the olfactory placode to the hypothalamus during embryonic development, coupled with abnormal development of the olfactory bulbs. This dual developmental defect leads to deficient secretion of LH and FSH from the pituitary gland, resulting in absent or incomplete puberty and infertility. [1,2,3]

The condition affects approximately 1 in 8,000 males and 1 in 40,000 females, with a male predominance of 4-5:1. Males typically present with absent pubertal development, micropenis, cryptorchidism, and infertility, while females present with primary amenorrhoea and absent breast development. The pathognomonic feature distinguishing Kallmann syndrome from normosmic isolated hypogonadotropic hypogonadism (nIHH) is the presence of olfactory dysfunction, which can be confirmed by MRI demonstrating olfactory bulb hypoplasia or aplasia. [1,2,12]

Kallmann syndrome exhibits complex genetic architecture with over 50 genes identified to date, including ANOS1 (KAL1), FGFR1, FGF8, PROKR2, PROK2, CHD7, and numerous others. Inheritance patterns include X-linked (10-15%), autosomal dominant, autosomal recessive, and oligogenic (digenic or trigenic mutations in 22% of cases), though approximately 50% of cases remain genetically unresolved despite comprehensive testing. [3,4,8,13]

Treatment comprises hormone replacement therapy for pubertal induction and maintenance, and gonadotropin therapy or pulsatile GnRH administration for fertility. Remarkably, 10-22% of patients may experience spontaneous reversal of hypogonadotropism, representing an intriguing example of neuroplasticity in the neuroendocrine system. With appropriate management, patients can achieve normal pubertal development, sexual function, bone health, and fertility in the majority of cases. [2,5,6,9]

Clinical Pearls

"Can't Smell + No Puberty = Kallmann": The combination of anosmia and absent puberty is the classic diagnostic clue. Always assess olfaction in delayed puberty.

"MRI is Diagnostic": Olfactory bulb hypoplasia/aplasia on brain MRI confirms the diagnosis and distinguishes KS from normosmic IHH.

"Test Smell Formally": Patients often don't recognise lifelong anosmia. Use standardised tests (UPSIT, Sniffin' Sticks), not clinical history alone.

"Fertility is Achievable": Unlike primary gonadal failure, 90% of males can achieve spermatogenesis with gonadotropin therapy, though it may take 12-24 months.

"Look for Associated Features": Cleft lip/palate, renal agenesis, mirror movements (synkinesia), hearing loss, and dental agenesis suggest specific genetic subtypes and guide testing.

"Constitutional Delay Mimics Early": Pre-pubertal LH/FSH may be low in both conditions. GnRH stimulation testing or watchful waiting distinguishes them.

"Reversal is Possible": 10-22% may spontaneously recover after treatment, more common in nIHH than KS. Monitor for spontaneous testosterone rise after withdrawal.

"Testicular Volume Predicts Fertility": Baseline testicular volume > 4 mL predicts better spermatogenic response to gonadotropin therapy.

---

2. Epidemiology

Demographics

Genetic Architecture

Associated Non-Reproductive Features

These features vary by genotype and aid in targeted genetic testing. [11,20]

---

3. Pathophysiology

Embryological Basis

The pathophysiology of Kallmann syndrome involves a unique developmental failure occurring during the first trimester of fetal life. [1,3]

Molecular Mechanisms

The genes implicated in Kallmann syndrome encode proteins involved in: [1,4,11]

1. GnRH Neuron Migration

   • Anosmin-1 (ANOS1/KAL1): Extracellular matrix glycoprotein; guides axonal pathfinding and neuronal migration
   • FGF8/FGFR1: Fibroblast growth factor signaling; essential for olfactory bulb development and GnRH neuron migration
   • Prokineticin-2/PROKR2: Chemoattractant signaling; guides GnRH neurons to hypothalamus

2. Olfactory System Development

   • Defects in the same pathways affect olfactory bulb morphogenesis
   • Results in olfactory bulb hypoplasia or complete aplasia (visible on MRI)

3. GnRH Receptor and Signaling

   • GNRHR: GnRH receptor mutations → normosmic IHH (no anosmia)
   • KISS1R, TAC3, TACR3: Upstream regulators of GnRH secretion

4. Oligogenic Inheritance

   • 22% of patients carry mutations in 2-3 genes (digenic/trigenic)
   • Explains phenotypic variability and incomplete penetrance
   • Modifier genes may influence severity [4,8]

Hormonal Axis in Kallmann Syndrome

HYPOTHALAMUS
    ↓ (GnRH) ← ❌ DEFICIENT (GnRH neurons absent/dysfunctional)
ANTERIOR PITUITARY
    ↓ (LH, FSH) ← LOW/ABSENT (No GnRH stimulation)
GONADS
    ↓ (Testosterone/Oestrogen) ← LOW (No gonadotropin stimulation)
    ↓
TARGET TISSUES
    ↓
❌ NO PUBERTY / NO SPERMATOGENESIS/OVULATION

Key Concept: The gonads themselves are typically structurally normal and potentially functional—they simply lack the hormonal stimulation (LH/FSH) required for development and function. This is why fertility is achievable with exogenous gonadotropin therapy. [1,2]

Hypogonadotropic vs Hypergonadotropic Hypogonadism

Kallmann Syndrome vs Normosmic IHH

Both represent congenital hypogonadotropic hypogonadism, but differ in olfactory phenotype:

Both conditions are treated similarly hormonally, but olfactory assessment and MRI distinguish them diagnostically. [1,2]

Mechanism of Reversal

An intriguing subset (10-22%) of CHH patients experience spontaneous reversal of hypogonadotropism after years of treatment. [2,5,6,15]

Proposed Mechanisms:

• Neuroplasticity: Late maturation of KNDy neurons (kisspeptin/neurokinin B/dynorphin neurons) in the arcuate nucleus, which regulate GnRH pulsatility
• Epigenetic changes: Environmental or hormonal factors may unmask latent GnRH neuron function
• Incomplete developmental defects: Partial migration allows delayed functional recovery
• Oligogenic modifiers: Additional genetic variants may permit conditional recovery

Predictors of Reversal: [5,6]

• Partial puberty achieved spontaneously before diagnosis
• Milder hormonal deficiency at baseline
• Normosmic IHH more likely than Kallmann syndrome
• Testicular volume > 4 mL at diagnosis

Clinical Implication: Monitor for spontaneous recovery by periodically withdrawing hormone therapy in select patients (e.g., every 2-3 years) and checking morning testosterone levels.

---

4. Clinical Presentation

Males

Infancy and Childhood

Note: Micropenis and cryptorchidism are clues to prenatal testosterone deficiency. These findings warrant endocrine evaluation, though diagnosis is often delayed until expected puberty fails to occur. [1,2]

Adolescence (Absent Puberty)

Adulthood (If Untreated)

Females

Adolescence

Adulthood (If Untreated)

Note: Females with Kallmann syndrome are often underdiagnosed or diagnosed later than males, as absence of breast development may be less immediately obvious than absent testicular development. [16]

Spectrum of Severity

Kallmann syndrome is not monolithic; phenotypic severity varies: [2,10,11]

Physical Examination Findings

Formal Olfactory Testing (Essential): [1,2]

• UPSIT (University of Pennsylvania Smell Identification Test): 40-item scratch-and-sniff test
• Sniffin' Sticks: Threshold, discrimination, and identification testing
• Self-reporting is unreliable: Patients with lifelong anosmia often don't recognise the deficit

---

5. Investigations

Diagnostic Strategy

The diagnosis of Kallmann syndrome is based on:

1. Clinical features: Absent/incomplete puberty + Anosmia
2. Biochemical confirmation: Low sex steroids with low/inappropriately normal gonadotropins
3. Olfactory confirmation: Formal smell testing + MRI evidence of olfactory bulb hypoplasia
4. Exclusion of other causes: Pituitary imaging, other pituitary hormones

Hormone Profile

Timing of Sampling: [1,2]

• Morning samples (8-9 AM) for testosterone (diurnal variation)
• Pooled samples: LH and FSH are pulsatile; some centres pool 3 samples at 20-minute intervals, but a single low value with low testosterone is usually sufficient
• Females: Sample in early follicular phase if any cycles occur (rare)

GnRH Stimulation Test (Optional)

Note: GnRH stimulation testing is less commonly used in modern practice; many centres rely on clinical follow-up and MRI findings. [1,2]

Olfactory Assessment

Critical: Always perform formal olfactory testing. Clinical history alone misses many cases. [1]

Imaging

MRI Brain (Olfactory-Focused Protocol)

Interpretation:

• Bilateral olfactory bulb aplasia: Pathognomonic for Kallmann syndrome
• Unilateral aplasia: Still consistent with diagnosis
• Normal olfactory bulbs: Suggests normosmic IHH, not Kallmann syndrome

Gold Standard: MRI confirmation of olfactory bulb hypoplasia/aplasia is diagnostic for Kallmann syndrome. [1,2,3]

MRI Pituitary

Renal Ultrasound

Genetic Testing

Phenotype-Guided Testing: [20]

• Renal agenesis + synkinesia: Test ANOS1 first
• CHARGE features (coloboma, heart defects, hearing loss): Test CHD7 first
• Cleft lip/palate: Test ANOS1, FGF8, FGFR1
• Family history: Consider inheritance pattern to prioritise genes

Genetic Counselling: Essential for family planning, recurrence risk, and reproductive options (PGD). [4]

Bone Density Assessment

Clinical Significance: Prolonged sex steroid deficiency leads to profound bone loss and fracture risk. Early diagnosis and treatment are critical. [1,2]

Additional Investigations (As Indicated)

---

6. Differential Diagnosis

Hypogonadotropic Hypogonadism (Low LH/FSH)

Hypergonadotropic Hypogonadism (High LH/FSH)

Critical Distinction: In Kallmann syndrome, LH/FSH are low or inappropriately normal (hypogonadotropic), whereas primary gonadal failure causes high LH/FSH (hypergonadotropic). This distinction determines whether fertility treatment is possible.

---

7. Management

Management Goals

1. Induce and maintain pubertal development (secondary sexual characteristics, bone health, psychosocial well-being)
2. Achieve fertility (when desired)
3. Prevent long-term complications (osteoporosis, cardiovascular disease, metabolic syndrome)
4. Provide psychological support (body image, relationships, sexual function)
5. Genetic counselling (family planning, recurrence risk)

Multidisciplinary Team

---

Pubertal Induction

Males

Objective: Induce virilisation, bone maturation, muscle development, psychological well-being.

Dosing Strategy: [1,2]

• "Start low, go slow": Begin with low doses to mimic natural puberty (gradual virilisation over 2-3 years)
• Monitor progression: Tanner staging, penile growth, voice deepening, muscle mass
• Bone age: Follow until epiphyses fuse (avoid premature closure with excessive doses)

Limitations of Testosterone Alone:

• ✅ Induces virilisation, muscle mass, bone density, libido
• ❌ Does NOT induce spermatogenesis (requires FSH and intratesticular testosterone)
• ❌ Does NOT increase testicular volume (testes remain small)

When to Switch to Gonadotropins (Males):

• If fertility desired, stop testosterone and start gonadotropin therapy (see below)
• Some clinicians use low-dose hCG alongside testosterone during pubertal induction to maintain testicular volume and prepare for future fertility [9]

Females

Objective: Induce breast development, uterine maturation, menstruation, bone health, psychological well-being.

Dosing Strategy: [1,2]

• Mimic Natural Puberty: Start with low-dose oestrogen to induce gradual breast development (thelarche) over 2-3 years
• Add Progesterone: When breakthrough bleeding occurs or after 1-2 years of oestrogen (to protect endometrium)
• Lifelong Treatment: Continue until natural menopause age (~50 years), then transition to standard HRT

Oral Contraceptive Pill (OCP) Alternative:

• Some clinicians use low-dose combined OCP for simplicity in older adolescents/adults
• Provides oestrogen + progestogen in a single formulation
• Caution: Ensure adequate oestrogen dose for bone health (standard OCP doses are lower than optimal for hypogonadism)

---

Fertility Treatment

The key distinction: Testosterone/Oestrogen replacement does NOT induce fertility. Fertility requires gonadotropin stimulation or pulsatile GnRH.

Males: Induction of Spermatogenesis

Step 1: Stop testosterone replacement (suppresses LH/FSH secretion).

Step 2: Initiate gonadotropin therapy.

Predictors of Success: [9,10]

• Testicular volume > 4 mL: Strong predictor of spermatogenic response
• Prior partial puberty: Better prognosis
• Inhibin B levels: Baseline Inhibin B > 35 pg/mL predicts response
• Prior cryptorchidism: May reduce success (testicular damage)

Monitoring:

• Semen analysis: Every 3 months until sperm appear
• Testosterone levels: Ensure adequate (gonadotropins stimulate intratesticular testosterone)
• Testicular volume: Should increase with treatment (to 8-15 mL)

Assisted Reproductive Technology (ART):

• ICSI (Intracytoplasmic Sperm Injection): Used if sperm counts remain very low (less than 5 million/mL)
• Testicular Sperm Extraction (TESE): Rarely needed; consider if no response to gonadotropins

Duration of Treatment:

• Continue gonadotropins until pregnancy achieved
• After successful conception, can switch back to testosterone replacement for ongoing virilisation/health

Cost and Logistics:

• Gonadotropin therapy is expensive and requires frequent self-injection (2-3× weekly)
• Patients need education on injection technique and realistic expectations regarding timeline

Females: Induction of Ovulation

Objective: Achieve ovulation and pregnancy.

Advantages of Pulsatile GnRH (Females): [1,2]

• ✅ Mimics natural physiology (physiological LH/FSH pulsatility)
• ✅ Lower risk of multiple pregnancy (typically mono-ovulation)
• ✅ Lower risk of OHSS (ovarian hyperstimulation syndrome)
• ❌ Requires subcutaneous pump (logistical burden)

Gonadotropin Protocol (If Pulsatile GnRH Unavailable):

• Start FSH 75-150 IU daily SC (adjust dose based on ovarian response)
• Monitor follicle development with transvaginal ultrasound
• When dominant follicle ≥18 mm, give hCG 5000-10,000 IU (trigger ovulation)
• Timed intercourse or intrauterine insemination (IUI)
• Risk: Multiple pregnancy (10-20%); OHSS (careful monitoring essential)

Assisted Reproductive Technology:

• IVF with ICSI: If male partner has infertility, tubal factors, or advanced maternal age
• Success rates: Comparable to general IVF population (no intrinsic oocyte defect in Kallmann syndrome)

Pregnancy and Post-Partum:

• Fertility treatment can be paused once pregnant
• Restart HRT post-partum (KS patients do not lactate due to lack of GnRH/prolactin surge priming)

---

Long-Term Maintenance Therapy

Males (Not Seeking Fertility)

Adverse Effects:

• Polycythaemia: Haematocrit > 54% → stop/reduce testosterone; consider therapeutic phlebotomy
• Prostate: Monitor PSA; avoid in known prostate cancer
• Liver: Oral testosterone (avoid; use IM/transdermal instead)
• Sleep apnoea: Testosterone may worsen; screen if symptoms
• Gynaecomastia: May develop (peripheral aromatisation); treat with dose adjustment or aromatase inhibitor (rarely needed)

Females (Not Seeking Fertility)

Duration: Continue HRT until age ~50 years (natural menopause age), then reassess need for continuation.

No Increased Breast Cancer Risk: Unlike HRT in postmenopausal women, HRT for hypogonadism in young women simply replaces deficient hormones to normal physiological levels. No evidence of increased breast cancer risk. [1,2]

---

Bone Health Management

Critical: Early diagnosis and treatment prevent irreversible bone loss. Delayed diagnosis (e.g., presenting in late 20s) may result in permanent osteoporosis despite HRT. [1,2]

---

Psychological and Psychosexual Support

Adolescent Considerations:

• Peer comparison (feeling "different")
• School absence for medical appointments
• Sports participation (may be affected by delayed puberty)
• Transition from paediatric to adult services (ensure continuity)

---

Monitoring for Reversal

Candidates for Reversal Monitoring: [5,6]

• Partial puberty before diagnosis
• Milder hormonal deficiency at baseline
• Normosmic IHH (higher reversal rate than KS)
• Testicular volume > 4 mL at diagnosis
• After several years of treatment (neuroplasticity may take time)

Frequency: Consider withdrawal trial every 2-3 years in selected patients.

Caution: Prolonged withdrawal risks bone loss; monitor DEXA if withdrawal > 6 months.

---

Management Algorithm

SUSPECTED KALLMANN SYNDROME
(Absent/Incomplete Puberty + Anosmia)
            ↓
DIAGNOSTIC WORKUP
- Hormones: LH, FSH, Testosterone/Oestradiol, Prolactin, TFTs, Cortisol
- Formal Smell Test (UPSIT, Sniffin' Sticks)
- MRI Brain (Olfactory Protocol) + MRI Pituitary
- Renal Ultrasound
- DEXA Scan
- Genetic Testing (Optional)
            ↓
DIAGNOSIS CONFIRMED
- Hypogonadotropic Hypogonadism (Low LH/FSH + Low Sex Steroids)
- Anosmia/Hyposmia (Formal testing + MRI olfactory bulb hypoplasia)
- Exclusion of other causes (Normal prolactin, normal pituitary, no tumour)
            ↓
MULTIDISCIPLINARY ASSESSMENT
- Endocrinology, Genetics, Psychology
- Assess associated features (renal, cardiac, hearing, cleft palate)
- Genetic counselling
            ↓
TREATMENT GOALS
1. Pubertal Induction/Maintenance
2. Fertility (When Desired)
3. Bone Health
4. Psychological Support
            ↓
┌──────────────────────────────────────────────────────────────┐
│  PUBERTAL INDUCTION / MAINTENANCE                            │
│  ┌─────────────────────┐  ┌─────────────────────────────┐   │
│  │ MALES               │  │ FEMALES                     │   │
│  │ - Testosterone      │  │ - Oestrogen (Start Low)     │   │
│  │   (Start Low-Dose)  │  │ - Add Progesterone After    │   │
│  │ - Increase Gradually│  │   1-2 Years                 │   │
│  │ - Adult Dose by     │  │ - Cyclical HRT Maintenance  │   │
│  │   2-3 Years         │  │                             │   │
│  └─────────────────────┘  └─────────────────────────────┘   │
│                                                              │
│  MONITORING:                                                 │
│  - Tanner Staging, Bone Age, Testosterone/Oestradiol        │
│  - DEXA Scan (Every 2 Years)                                │
│  - Psychological Assessment                                  │
└──────────────────────────────────────────────────────────────┘
            ↓
WHEN FERTILITY DESIRED
            ↓
┌──────────────────────────────────────────────────────────────┐
│  FERTILITY TREATMENT                                         │
│  ┌─────────────────────┐  ┌─────────────────────────────┐   │
│  │ MALES               │  │ FEMALES                     │   │
│  │ 1. STOP Testosterone│  │ 1. STOP HRT                 │   │
│  │ 2. START:           │  │ 2. START:                   │   │
│  │    - hCG Alone OR   │  │    - Pulsatile GnRH (Pump)  │   │
│  │    - hCG + FSH/hMG  │  │      OR                     │   │
│  │      OR             │  │    - Gonadotropins (FSH +   │   │
│  │    - Pulsatile GnRH │  │      hCG Trigger)           │   │
│  │ 3. Monitor:         │  │ 3. Monitor:                 │   │
│  │    - Semen Analysis │  │    - Follicle Tracking (USS)│   │
│  │    - Testicular Vol │  │    - Oestradiol Levels      │   │
│  │ 4. ICSI if Needed   │  │ 4. IVF if Needed            │   │
│  │                     │  │                             │   │
│  │ Timeline: 8-9 Months│  │ Success: 80-90% Pregnancy   │   │
│  │ Success: ~90% Sperm │  │                             │   │
│  └─────────────────────┘  └─────────────────────────────┘   │
└──────────────────────────────────────────────────────────────┘
            ↓
POST-FERTILITY
- Resume Testosterone/HRT Maintenance
- Long-Term Monitoring (Bone, Metabolic, Psychological)
            ↓
CONSIDER REVERSAL TRIAL
- Every 2-3 Years in Selected Patients
- Withdraw HRT × 3-6 Months → Monitor Testosterone/Oestradiol
- If Reversal: Continue Monitoring (May Re-Decline)
- If No Reversal: Resume HRT

---

8. Complications

Untreated or Delayed Treatment

Treatment-Related Complications

Long-Term Health Risks

---

9. Prognosis and Outcomes

Pubertal Development

Fertility Outcomes

Critical Insight: Fertility is achievable in the vast majority of Kallmann syndrome patients, unlike primary gonadal failure (Klinefelter, Turner). This is a key counselling point. [1,2,9]

Reversal and Neuroplasticity

Clinical Implication: Consider periodic withdrawal trials (every 2-3 years) in selected patients to assess for reversal. [5,6]

Quality of Life

Barriers to Optimal Outcomes:

• Delayed diagnosis: Irreversible bone loss; psychological impact of prolonged untreated hypogonadism
• Non-adherence: Lifelong HRT required; some patients discontinue treatment
• Financial barriers: Gonadotropin therapy expensive (not always funded)
• Access to specialist care: Fertility treatment requires expert reproductive endocrinology

---

10. Evidence and Guidelines

Key Clinical Trials and Cohort Studies

International Guidelines

Evidence Levels by Intervention

---

11. Special Populations and Considerations

Pregnancy and Kallmann Syndrome

Paediatric Considerations

Female-Specific Issues

Genetic and Reproductive Counselling

Reversal Candidates

Protocol: Withdraw HRT for 3-6 months every 2-3 years; monitor testosterone/oestradiol weekly × 4 weeks; if spontaneous rise, continue off HRT with monitoring; if re-decline or no rise, resume HRT. [5,6]

---

12. Patient and Layperson Explanation

What is Kallmann Syndrome?

Kallmann Syndrome is a rare genetic condition that affects puberty and the sense of smell. People with Kallmann Syndrome do not go through puberty naturally because their body does not make enough of the hormones that trigger puberty. They also have a reduced or absent sense of smell (anosmia), which is a key clue to the diagnosis.

What causes it?

Before you were born, special nerve cells (called GnRH neurons) are supposed to move from the nose area to a part of the brain called the hypothalamus. These nerve cells are responsible for starting puberty. In Kallmann Syndrome, these nerve cells do not move to the right place, so puberty does not start on its own. The same problem also affects the development of the part of the brain that controls smell, which is why people with Kallmann Syndrome cannot smell (or have a reduced sense of smell).

Is it genetic?

Yes, Kallmann Syndrome is usually caused by genetic changes (mutations). It can run in families, but many cases occur sporadically (the person is the first in their family to have it). There are many different genes that can cause Kallmann Syndrome, and scientists have identified over 50 different genes so far. Sometimes the inheritance pattern is X-linked (affecting mainly boys), but it can also be autosomal dominant, autosomal recessive, or involve multiple genes.

What are the signs and symptoms?

In boys:

• Puberty does not start by age 14 (no growth spurt, voice stays high, no facial hair or body hair)
• Penis and testicles remain small
• Difficulty having children later in life
• Cannot smell, or reduced sense of smell (often not noticed because it has been present since birth)

In girls:

• Periods do not start (primary amenorrhoea)
• Breasts do not develop
• Difficulty having children later in life
• Cannot smell, or reduced sense of smell

Other possible features (depending on the genetic cause):

• Cleft lip or cleft palate
• Missing a kidney (usually just one side; the other kidney works normally)
• Mirror movements (when you move one hand, the other hand moves involuntarily in the same way)
• Hearing loss
• Missing teeth

How is it diagnosed?

Doctors will:

1. Do blood tests to check hormone levels (testosterone in boys, oestrogen in girls, and pituitary hormones LH and FSH)
2. Test your sense of smell formally (using standardised smell tests, because many people do not realise they cannot smell)
3. Do an MRI scan of the brain to look at the smell-related structures (olfactory bulbs) and the pituitary gland
4. Do an ultrasound of the kidneys to check if both kidneys are present
5. Genetic testing (optional) to identify the specific gene involved

Is there treatment?

Yes! Kallmann Syndrome is very treatable.

For puberty:

• Boys receive testosterone (by injection, gel, or patches) to develop male characteristics (deeper voice, muscle growth, body hair, etc.)
• Girls receive oestrogen and progesterone (hormone replacement therapy) to develop breasts, start periods, and protect bone health
• Treatment is lifelong but allows completely normal development

For fertility (having children):

• Boys can receive special hormone injections (called gonadotropins or GnRH) that stimulate the testicles to make sperm. This takes about 8-12 months, but 90% of men can produce sperm and father children (often with the help of fertility treatment like IVF).
• Girls can receive hormone injections or a hormone pump to stimulate the ovaries to release eggs. Success rates are very high (80-90% can get pregnant).
• The key message: Fertility is achievable with treatment, even though natural fertility is not possible.

For bone health:

• Adequate hormone replacement protects bones
• Calcium and vitamin D supplements
• Regular exercise

Will I need treatment forever?

Most people need lifelong hormone replacement to maintain puberty, bone health, and overall well-being. However, interestingly, about 10-20% of people may spontaneously recover after years of treatment, meaning their body starts making hormones on its own. Doctors may periodically test for this by temporarily stopping treatment and checking hormone levels.

Can I live a normal life?

Yes, absolutely. With treatment, people with Kallmann Syndrome can:

• Go through puberty and develop normally
• Have healthy bones and muscles
• Have normal sexual function and relationships
• Have children (with fertility treatment)
• Live a full, healthy life

The key is early diagnosis and consistent treatment. Many people with Kallmann Syndrome lead completely normal lives—they go to school, work, get married, and have families.

What about my children?

The risk of passing Kallmann Syndrome to your children depends on the specific genetic cause:

• X-linked (ANOS1/KAL1 gene): If you are a boy with this type, your daughters will be carriers and your sons will not be affected. If you are a girl who is a carrier, each son has a 50% chance of being affected.
• Autosomal dominant: Each child has a 50% chance of inheriting the condition.
• Autosomal recessive: Your children will be carriers unless your partner is also a carrier or affected.
• Oligogenic (multiple genes): Risk is hard to predict; genetic counselling is essential.

Genetic counselling can help you understand your specific risk and discuss options like genetic testing and assisted reproduction with genetic screening (preimplantation genetic diagnosis).

Where can I get support?

• Endocrinology specialists: Hormone replacement and fertility treatment
• Fertility clinics: When you are ready to have children
• Genetic counsellors: Understand your genetic risk and family planning
• Psychologists: Help with body image, relationships, and emotional challenges
• Patient support groups: Connect with others who have Kallmann Syndrome

Key Takeaways

✅ Kallmann Syndrome is rare but very treatable
✅ You can go through puberty with hormone treatment
✅ You can have children with fertility treatment (90% success in males, 80-90% in females)
✅ You can live a completely normal, healthy life
✅ Early diagnosis and consistent treatment are key
✅ You are not alone—support is available

---

13. References

Primary Sources

1. Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11(9):547-564. doi:10.1038/nrendo.2015.112. PMID: 26194704.

2. Young J, Xu C, Papadakis GE, et al. Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocr Rev. 2019;40(2):669-710. doi:10.1210/er.2018-00116. PMID: 30742578.

3. Dodé C, Hardelin JP. Kallmann syndrome. Eur J Hum Genet. 2009;17(2):139-146. doi:10.1038/ejhg.2008.206. PMID: 18781183.

4. Maione L, Dwyer AA, Francou B, et al. GENETICS IN ENDOCRINOLOGY: Genetic counseling for congenital hypogonadotropic hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing. Eur J Endocrinol. 2018;178(3):R55-R80. doi:10.1530/EJE-17-0749. PMID: 28651390.

5. Dwyer AA, Raivio T, Pitteloud N. MANAGEMENT OF ENDOCRINE DISEASE: Reversible hypogonadotropic hypogonadism. Eur J Endocrinol. 2016;174(6):R267-R274. doi:10.1530/EJE-15-1033. PMID: 27150496.

6. Raivio T, Falardeau J, Dwyer A, et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med. 2007;357(9):863-873. doi:10.1056/NEJMoa066494. PMID: 17761591.

7. Quinton R, Mamoojee Y, Jayasena CN, et al. Society for Endocrinology UK guidance on the initial evaluation of a suspected difference or disorder of sex development (Revised 2021). Clin Endocrinol (Oxf). 2022;96(3):340-352. doi:10.1111/cen.14550. PMID: 34546590.

8. Sykiotis GP, Plummer L, Hughes VA, et al. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci USA. 2010;107(34):15140-15144. doi:10.1073/pnas.1009622107. PMID: 20696889.

9. Liu PY, Baker HWG, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab. 2009;94(3):801-808. doi:10.1210/jc.2008-1648. PMID: 19066300.

10. Pitteloud N, Hayes FJ, Boepple PA, DeCruz S, Seminara SB, MacLaughlin DT, Crowley WF Jr. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002;87(1):152-160. doi:10.1210/jcem.87.1.8131. PMID: 11788639.

11. Stamou MI, Georgopoulos NA. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. Metabolism. 2018;86:124-134. doi:10.1016/j.metabol.2017.10.012. PMID: 29102522.

12. Bonomi M, Vezzoli V, Krausz C, et al. Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH). Eur J Endocrinol. 2018;178(1):23-32. doi:10.1530/EJE-17-0065. PMID: 29079730.

13. Oliveira LM, Seminara SB, Beranova M, Hayes FJ, Valkenburgh SB, Schipani E, Costa EM, Latronico AC, Crowley WF Jr, Vallejo M. The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J Clin Endocrinol Metab. 2001;86(4):1532-1538. doi:10.1210/jcem.86.4.7420. PMID: 11297579.

14. Cassatella D, Howard SR, Acierno JS, et al. Congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty have distinct genetic architectures. Eur J Endocrinol. 2018;178(4):377-388. doi:10.1530/EJE-17-0568. PMID: 29371353.

15. Xu C, Messina A, Somm E, et al. KNDy neurons in the arcuate nucleus of the hypothalamus are required for the restoration of reproductive function in Kallmann syndrome. J Clin Invest. 2020;130(6):3122-3135. doi:10.1172/JCI133571. PMID: 32191639.

16. Shaw ND, Seminara SB, Welt CK, et al. Expanding the phenotype and genotype of female GnRH deficiency. J Clin Endocrinol Metab. 2011;96(3):E566-E576. doi:10.1210/jc.2010-2292. PMID: 21209029.

17. Tommiska J, Kansakoski J, Christiansen P, et al. Genetics of congenital hypogonadotropic hypogonadism in Denmark. Eur J Med Genet. 2014;57(7):345-348. doi:10.1016/j.ejmg.2014.04.002. PMID: 24747089.

18. Salian-Mehta S, Xu M, Knox AM, Hietpas M, Bliesner B, Berga SL. Functional hypothalamic amenorrhea and its influence on women's health. J Endocr Soc. 2019;3(11):2168-2184. doi:10.1210/js.2019-00164. PMID: 31681851.

19. Laitinen EM, Tommiska J, Sane T, Vaaralahti K, Toppari J, Raivio T. Reversible congenital hypogonadotropic hypogonadism in patients with CHD7, FGFR1 or GNRHR mutations. PLoS One. 2012;7(6):e39450. doi:10.1371/journal.pone.0039450. PMID: 22761799.

20. Costa-Barbosa FA, Balasubramanian R, Keefe KW, et al. Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes. J Clin Endocrinol Metab. 2013;98(5):E943-E953. doi:10.1210/jc.2012-4393. PMID: 23546242.

---

14. Examination Focus

High-Yield Facts for Exams (MRCP, FRACP, USMLE, PLAB)

Defining Features

Q: What is the classic diagnostic triad of Kallmann Syndrome?
A:

1. Hypogonadotropic Hypogonadism (Low LH/FSH + Low Testosterone/Oestrogen)
2. Anosmia or Hyposmia (Absent or reduced sense of smell)
3. MRI: Olfactory Bulb Hypoplasia/Aplasia

Pathophysiology

Q: What is the underlying embryological defect in Kallmann Syndrome?
A: Failure of GnRH neuron migration from the olfactory placode to the hypothalamus during weeks 6-12 of fetal development, coupled with abnormal olfactory bulb development.

Genetics

Q: What is the inheritance pattern of ANOS1 (KAL1) mutations, and what are the associated features?
A:

• Inheritance: X-linked recessive (affects mainly males)
• Associated features:
  • Unilateral renal agenesis (30-40%)
  • Synkinesia (mirror movements) (75%)
  • Cleft lip/palate

Q: What percentage of Kallmann syndrome cases are genetically unresolved despite comprehensive testing?
A: ~40-50% (despite > 50 genes identified, genetic cause remains unknown in half of cases).

Q: What is oligogenic inheritance, and how common is it in Kallmann syndrome?
A: Digenic or trigenic mutations (mutations in 2-3 genes simultaneously) account for 22% of CHH cases, explaining phenotypic variability and incomplete penetrance. [8]

Clinical Presentation

Q: How do you distinguish Kallmann Syndrome from Constitutional Delay of Growth and Puberty (CDGP)?
A:

Q: What physical sign suggests ANOS1 mutations in Kallmann syndrome?
A: Bimanual synkinesia (mirror movements): involuntary mirroring of hand movements when performing unilateral tasks. Seen in 75% of ANOS1 mutations.

Investigations

Q: What is the gold-standard imaging finding for Kallmann syndrome?
A: MRI brain demonstrating olfactory bulb hypoplasia or aplasia (bilateral or unilateral). Sensitivity ~90%.

Q: What hormone pattern distinguishes hypogonadotropic from hypergonadotropic hypogonadism?
A:

• Hypogonadotropic (Kallmann): Low LH/FSH + Low sex steroids
• Hypergonadotropic (e.g., Klinefelter, Turner): High LH/FSH + Low sex steroids

Management

Q: Why does testosterone replacement NOT restore fertility in males with Kallmann syndrome?
A: Exogenous testosterone suppresses LH and FSH secretion via negative feedback, and does NOT provide the intratesticular testosterone concentrations or FSH stimulation required for spermatogenesis.

Q: What is the first-line fertility treatment for males with Kallmann syndrome, and what is the expected timeline to spermatogenesis?
A:

• hCG (alone or with FSH/hMG) or Pulsatile GnRH
• Timeline: Median 8-9 months (range 4-24 months)
• Success: ~90% achieve spermatogenesis [9]

Q: What predicts successful spermatogenesis in males with Kallmann syndrome?
A:

• Testicular volume > 4 mL at baseline (strongest predictor) [9]
• Prior partial puberty
• Absence of cryptorchidism
• Inhibin B > 35 pg/mL

Q: Why is pulsatile GnRH preferred over gonadotropins for ovulation induction in females with Kallmann syndrome?
A:

• ✅ Lower risk of OHSS (ovarian hyperstimulation syndrome)
• ✅ Lower risk of multiple pregnancy (mono-ovulation typical)
• ✅ Mimics physiological GnRH pulsatility
• ❌ Requires subcutaneous pump (logistical burden)

Complications

Q: What is the most important long-term complication of untreated Kallmann syndrome?
A: Severe osteoporosis with early-onset fragility fractures due to prolonged sex steroid deficiency. Early diagnosis and adequate HRT are critical for bone health.

Prognosis

Q: What percentage of patients with congenital hypogonadotropic hypogonadism experience spontaneous reversal?
A: 10-22% (lower in Kallmann syndrome ~10%; higher in normosmic IHH ~20-22%). Mechanism: neuroplasticity and KNDy neuron maturation. [2,5,6,15]

Q: Is fertility achievable in Kallmann syndrome?
A: Yes, in 80-90% of patients with appropriate gonadotropin or pulsatile GnRH therapy. This is a key distinction from primary gonadal failure (Klinefelter, Turner).

---

Viva Voce Scenarios

Scenario 1: Male with Delayed Puberty

Examiner: "A 16-year-old boy presents with absent pubertal development. How would you approach this case?"

Model Answer:

1. History:
   • Age of expected puberty onset (Tanner staging, testicular volume)
   • Family history of delayed puberty
   • Sense of smell (key question!)
   • Growth pattern
   • Chronic illness, medications, nutritional status
   • Neonatal history (cryptorchidism, micropenis)
2. Examination:
   • Tanner staging (prepubertal = stage 1)
   • Testicular volume (orchidometer: less than 4 mL = prepubertal)
   • Eunuchoid proportions (arm span > height)
   • Formal smell testing (UPSIT)
   • Synkinesia (mirror movements)
   • Midline defects (cleft palate)
3. Investigations:
   • Hormones: LH, FSH, Testosterone (8 AM), Prolactin, TSH, Free T4
   • MRI Brain (olfactory-focused protocol + pituitary)
   • Renal Ultrasound (unilateral agenesis screening)
   • DEXA Scan (bone density)
   • Karyotype (exclude Klinefelter if testes very small)
   • Genetic testing (if Kallmann suspected)
4. Differential Diagnosis:
   • Kallmann Syndrome (if anosmia present)
   • Normosmic IHH
   • Constitutional delay (family history; watchful waiting)
   • Klinefelter (47,XXY): High LH/FSH
   • Hypopituitarism (check other pituitary hormones)
5. Management:
   • If Kallmann confirmed: Testosterone replacement for pubertal induction
   • Multidisciplinary team: Endocrinology, genetics, psychology
   • Counselling: Lifelong treatment; fertility achievable

Key Mistake to Avoid: Forgetting to ask about sense of smell. This is the critical clue to Kallmann syndrome.

Scenario 2: Fertility Counselling

Examiner: "A 28-year-old man with Kallmann syndrome on testosterone replacement presents wanting to father a child. What do you advise?"

Model Answer:

1. Explain Fertility Potential:
   • "Good news: ~90% of men with Kallmann syndrome can produce sperm with treatment."
   • "However, testosterone replacement does NOT produce sperm—we need to switch to different hormones."
2. Treatment Plan:
   • Stop testosterone (suppresses LH/FSH)
   • Start hCG injections (1500-3000 IU SC 2-3×/week)
   • If no sperm after 6-12 months, add FSH (75-150 IU SC 2-3×/week)
   • Alternative: Pulsatile GnRH pump
3. Timeline:
   • Median 8-9 months to sperm appearance (range 4-24 months)
   • "This requires patience and commitment."
4. Predictors of Success:
   • "Your testicular volume is > 4 mL, which is a good sign."
   • Check Inhibin B (> 35 pg/mL predicts success)
5. Monitoring:
   • Semen analysis every 3 months
   • Testosterone levels (ensure adequate from hCG)
   • Testicular volume (should increase to 8-15 mL)
6. Assisted Reproduction:
   • If sperm counts remain low: ICSI (Intracytoplasmic Sperm Injection)
   • Rarely: Testicular sperm extraction (TESE)
7. Cost and Logistics:
   • "Gonadotropin injections are expensive and require self-injection 2-3 times per week."
   • "Once pregnancy is achieved, we switch back to testosterone."
8. Genetic Counselling:
   • "We can discuss the risk of passing this condition to your children."
   • Consider genetic testing and preimplantation genetic diagnosis (PGD) if desired.

---

OSCE Stations

Station: Communication—Breaking the Diagnosis

Task: Explain the diagnosis of Kallmann syndrome to an 18-year-old male patient.

Mark Scheme:

1. ✅ Introduce self and establish rapport
2. ✅ Assess patient's understanding: "What has been explained to you so far?"
3. ✅ Explain diagnosis in lay terms:
   • "You have a condition called Kallmann syndrome, which affects puberty and your sense of smell."
   • "It's caused by a problem with certain nerve cells that didn't develop properly before you were born."
4. ✅ Explain why puberty hasn't happened:
   • "These nerve cells are supposed to tell your body to make hormones that start puberty."
   • "Without them, puberty doesn't start on its own."
5. ✅ Explain the anosmia:
   • "The same problem affects the part of your brain that controls smell, which is why you can't smell."
6. ✅ Reassure about treatment:
   • "The good news is that this is very treatable."
   • "We can give you hormone treatment (testosterone) that will help you go through puberty."
7. ✅ Address fertility:
   • "Many young men worry about having children in the future."
   • "With special fertility treatment, 90% of men with Kallmann syndrome can father children."
8. ✅ Address psychological impact:
   • "I understand this may be a lot to take in."
   • "We have a team to support you, including psychologists."
9. ✅ Offer written information and follow-up
10. ✅ Check understanding and invite questions

---

SBA (Single Best Answer) Practice Questions

Question 1

A 17-year-old male presents with absent pubertal development. On examination, he has no facial hair, high-pitched voice, testicular volume 3 mL bilaterally, and arm span 6 cm greater than height. Hormonal investigations show LH 1.2 IU/L (normal 1.5-9.3), FSH 1.4 IU/L (normal 1.4-18.1), and testosterone 2.1 nmol/L (normal 10-35). He reports lifelong inability to smell. What is the MOST likely diagnosis?

A. Constitutional delay of growth and puberty
B. Klinefelter syndrome
C. Kallmann syndrome
D. Isolated growth hormone deficiency
E. Prolactinoma

Answer: C. Kallmann syndrome

Explanation: The combination of hypogonadotropic hypogonadism (low LH/FSH + low testosterone) with anosmia is diagnostic of Kallmann syndrome. Eunuchoid proportions (arm span > height) indicate delayed epiphyseal fusion due to sex steroid deficiency. Constitutional delay would have a family history and eventual spontaneous puberty. Klinefelter has high LH/FSH (hypergonadotropic). GH deficiency causes short stature, not delayed puberty. Prolactinoma would have elevated prolactin.

---

Question 2

A 25-year-old man with Kallmann syndrome on testosterone replacement therapy wishes to father a child. What is the MOST appropriate next step in management?

A. Continue testosterone and add clomiphene citrate
B. Stop testosterone and start hCG injections
C. Continue testosterone and refer for intracytoplasmic sperm injection (ICSI)
D. Stop testosterone and start sildenafil
E. Continue testosterone and add anastrozole

Answer: B. Stop testosterone and start hCG injections

Explanation: Testosterone replacement suppresses LH and FSH and does NOT induce spermatogenesis. To achieve fertility, testosterone must be stopped and replaced with hCG (which stimulates intratesticular testosterone and spermatogenesis). If hCG alone fails after 6-12 months, FSH is added. Clomiphene is ineffective in central hypogonadism. ICSI is premature (first attempt spermatogenesis induction). Sildenafil treats erectile dysfunction, not infertility. Anastrozole is an aromatase inhibitor, not indicated.

---

Question 3

Which of the following imaging findings is MOST specific for Kallmann syndrome?

A. Pituitary adenoma
B. Empty sella turcica
C. Olfactory bulb aplasia
D. Enlarged pituitary gland
E. Normal brain MRI

Answer: C. Olfactory bulb aplasia

Explanation: Olfactory bulb hypoplasia or aplasia on MRI is the gold-standard diagnostic finding for Kallmann syndrome (~90% sensitive). It distinguishes KS from normosmic IHH (which has normal olfactory bulbs). Pituitary adenoma suggests prolactinoma or other pituitary tumours. Empty sella suggests hypopituitarism. Enlarged pituitary is non-specific. Normal brain MRI excludes Kallmann (would suggest normosmic IHH instead).

---

Question 4

A 19-year-old woman with primary amenorrhoea and absent breast development undergoes hormonal evaluation. LH is 1.8 IU/L, FSH 2.1 IU/L, and oestradiol 15 pmol/L. Karyotype is 46,XX. She reports inability to smell since childhood. What is the MOST likely inheritance pattern if genetic testing identifies an ANOS1 (KAL1) mutation?

A. Autosomal dominant
B. Autosomal recessive
C. X-linked recessive
D. Mitochondrial
E. Sporadic (de novo)

Answer: C. X-linked recessive

Explanation: ANOS1 (KAL1) mutations cause X-linked recessive Kallmann syndrome. While males are more commonly affected (hemizygous), females can be affected if they have homozygous mutations (rare) or skewed X-inactivation. ANOS1 is associated with unilateral renal agenesis, synkinesia (mirror movements), and cleft lip/palate.

---

Revision Mnemonics

"CAN'T SMELL = CAN'T PUBERTY"

• Congenital hypogonadotropic hypogonadism
• Anosmia (key clue!)
• No GnRH neurons (migration failure)
• Testosterone/oestrogen deficiency
• Small testes/infantile uterus
• MRI: olfactory bulb hypoplasia
• Eunuchoid proportions
• Low LH/FSH
• Lifelong HRT required

Associated Features (ANOS1): "CRUMB"

• Cleft lip/palate
• Renal agenesis (unilateral)
• Undescended testes (cryptorchidism)
• Mirror movements (synkinesia)
• Bimanual synkinesis

Fertility Treatment (Males): "hCG First, FSH Next"

• Start hCG alone (1500-3000 IU SC 2-3×/week)
• If no sperm after 6-12 months, add FSH (75-150 IU SC 2-3×/week)
• Median 8-9 months to sperm
• 90% achieve spermatogenesis
• Testicular volume > 4 mL predicts success

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists. Kallmann syndrome requires lifelong specialist endocrinology and reproductive medicine input.